The Multi-center, Randomized and Controlled Phase II Trial of Apatinib Mesylate Tablets Combined With PD-1 Antibody SHR-1210 for Adjuvant Treatment of Patients With High Recurrence Risk After Radical Operation of Hepatocellular Carcinoma
Latest Information Update: 03 Mar 2023
At a glance
- Drugs Camrelizumab (Primary) ; Rivoceranib (Primary) ; Epirubicin; Oxaliplatin
- Indications Liver cancer
- Focus Therapeutic Use
Most Recent Events
- 13 Sep 2022 Results (At date cut off: 4 Mar 2022; n=82) assessing he efficacy and safety of anti-PD-1 antibody SHR-1210 combined with apatinib as adjuvant treatment versus hepatic arterial infusion (HAI) in hepatocellular carcinoma patients with high risk of recurrence after radical resection, presented at the 47th European Society for Medical Oncology Congress.
- 17 Jan 2021 Status changed from not yet recruiting to recruiting ,as per preliminary results presented at the 2021 Gastrointestinal Cancers Symposium
- 17 Jan 2021 Preliminary results (n=32) presented at the 2021 Gastrointestinal Cancers Symposium